4//SEC Filing
Hamel Lawrence G 4
Accession 0000899243-19-026513
CIK 0001427925other
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 6:05 AM ET
Size
11.3 KB
Accession
0000899243-19-026513
Insider Transaction Report
Form 4
Hamel Lawrence G
Chief Development Officer
Transactions
- Award
Stock Option (Right to Buy)
2019-11-02+26,125→ 52,250 totalExercise: $2.23From: 2019-11-02Exp: 2028-11-02→ Common Stock (26,125 underlying)
Holdings
- 83,382
Common Stock
- 29,795(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]Balance includes non-reportable acquisition of 5,329 shares of Common Stock through the Company's Employee Stock Purchase Plan.
- [F2]On April 7, 2018, the reporting person was granted a performance-based option to purchase 52,250 shares of common stock, subject to the Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019. Once the performance criteria is achieved, the option vests in two equal installments with 50% of the option vesting upon the Company's achievement of the performance criteria and the remaining 50% of the option vesting on the one-year anniversary of the date of such achievement, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 26,125 shares on that date. On November 2, 2019, the remaining balance of the option vested.
Issuer
ACELRX PHARMACEUTICALS INC
CIK 0001427925
Entity typeother
Related Parties
1- filerCIK 0001511368
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 7:00 PM ET
- Accepted
- Nov 4, 6:05 AM ET
- Size
- 11.3 KB